Cytomegalovirus (CMV) is a major cause of morbidity and mortality in solid organ transplant recipients. Approximately 60% of adults are CMV seropositive, indicating previous exposure. Following resolution of the primary infection, CMV remains in a latent state. Reactivation is controlled by memory T cells in healthy individuals; transplant recipients have reduced memory T cell function due to chronic immunosuppressive therapies. In this study, CD8 + T cell responses to CMV polypeptides immediate-early-1 and pp65 were analyzed in 16 CMV-seropositive kidney and heart transplant recipients longitudinally pretransplantation and posttransplantation. All patients received standard of care maintenance immunosuppression, antiviral prophylaxis, and CMV viral load monitoring, with approximately half receiving T cell-depleting induction therapy. The frequency of CMVresponsive CD8 + T cells, defined by the production of effector molecules in response to CMV peptides, increased during the course of 1 year posttransplantation. The increase commenced after the completion of antiviral prophylaxis, and these T cells tended to be terminally differentiated effector cells. Based on this small cohort, these data suggest that even in the absence of disease, antigenic exposure may continually shape the CMV-responsive T cell population posttransplantation.
Cytomegalovirus (CMV) is a major cause of morbidity and mortality in solid organ transplant recipients. Approximately 60% of adults are CMV seropositive, indicating previous exposure. Following resolution of the primary infection, CMV remains in a latent state. Reactivation is controlled by memory T cells in healthy individuals; transplant recipients have reduced memory T cell function due to chronic immunosuppressive therapies. In this study, CD8 + T cell responses to CMV polypeptides immediate-early-1 and pp65 were analyzed in 16 CMV-seropositive kidney and heart transplant recipients longitudinally pretransplantation and posttransplantation. All patients received standard of care maintenance immunosuppression, antiviral prophylaxis, and CMV viral load monitoring, with approximately half receiving T cell-depleting induction therapy. The frequency of CMVresponsive CD8 + T cells, defined by the production of effector molecules in response to CMV peptides, increased during the course of 1 year posttransplantation. The increase commenced after the completion of antiviral prophylaxis, and these T cells tended to be terminally differentiated effector cells. Based on this small cohort, these data suggest that even in the absence of disease, antigenic exposure may continually shape the CMV-responsive T cell population posttransplantation.
Introduction
Immunosuppression places transplant recipients at an elevated risk of disease associated with viral infections that establish latency, such as cytomegalovirus (CMV). Standard of care to protect recipients from CMV disease consists of frequent monitoring for viremia and treatment with antiviral agents, or antiviral prophylaxis for up to 1 year posttransplantation (1) (2) (3) (4) . These therapeutic interventions have reduced the incidence of viremia and CMV disease (1, 4) , but side effects, including leukopenia, complicate immunosuppressive management (3, 5) . In heart and kidney transplant recipients, damage to the allograft contributes to decreased graft function and correlates with increased incidence of rejection (6, 7) .
Resolution of primary CMV infection by natural killer, B, and T cells (8) is followed by long-term viral latency in CD34
+ bone marrow cells and monocytes (8, 9) . CMV reactivation is incompletely understood but is known to occur when latently infected cells differentiate (8, 10) . Viral spread is typically restricted by memory T cell responses (8) . While reactivation does not lead to disease in healthy individuals, it does result in expansion of CMV-specific memory T cells with age, a phenomenon termed "memory inflation" (11, 12) . As many as 40% of the CD8 + T cell repertoire may be CMV reactive in older individuals (13) (14) (15) .
to IE-1 and pp65 are the most thoroughly studied responses, as reviewed elsewhere (18) . Studies in transplant recipients have largely relied on interferon-(IFN)c production to quantify T cell responses to CMV. Research on T cell responses to viral infections, including HIV, hepatitis C virus, and Epstein-Barr virus, indicates that the production of multiple inflammatory cytokines and cytolytic proteins is important to viral control (19) (20) (21) . Cells with multiple functions are called polyfunctional cells. In healthy CMV-seropositive individuals, responses to CMV are maintained and the polyfunctional T cell population expands with time (11) . Polyfunctionality is elevated in CMV-specific memory T cells, in contrast to HIV-specific memory T cells (22) . Little is known about the role of polyfunctional CMV-responsive T cells in solid organ transplant recipients. T cell polyfunctionality could be more predictive of protection against CMV than the production of IFNc alone. Thus, a better understanding of T cell responses in immunosuppressed transplant patients may improve clinical care and outcomes. In these studies, we analyzed polyfunctionality and specificity of CMV-responsive T cells in solid organ transplant recipients pretransplantation and posttransplantation.
Materials and Methods

Human subjects
Patients were enrolled at the University of Pennsylvania immediately before transplantation. Blood samples were collected pretransplantation (day 0) and at intervals of 30, 90, 180, 270, and 360 days posttransplantation. This study was subject to institutional review board approval at the University of Pennsylvania under protocol 817637, and all patients gave informed consent before participating in the study. All identifiable information was blinded to those performing experiments. Deidentified normal donor samples were obtained from the University of Pennsylvania Human Immunology Core and the Stanford Blood Center. All patients were screened for CMV serostatus.
The cohort consisted of kidney and heart transplant recipients (Table 1) . These populations were selected due to their similar immunosuppressive regimens and differing induction therapy. Standard of care immunosuppressive therapy was controlled by the treating physicians. The patients reported in this study are limited to recipients who were CMV seropositive at the time of transplantation (Table 1) , with a mix of seropositive and seronegative donors (Table 2) . One seropositive recipient (patient 9) had documented CMV viremia 2 years before transplantation and was undergoing immunomodulatory treatment for ulcerative colitis at the time of transplantation; this subject was excluded from analysis. Another recipient, patient 17, was excluded from Figures 1-4 and S3-S4 due to an episode of CMV viremia (Table S1 ). After these exclusions, 16 transplant recipients remained. Day 30 samples were excluded due to low cell numbers.
Blood collection and processing
Blood was collected in vacutainer tubes with EDTA as an anticoagulant for the isolation of peripheral blood mononuclear cells (PBMCs) or with clot activator for the isolation of serum. All transplant recipient samples and a subset of normal donor samples were processed at the University of Pennsylvania Human Immunology Core. The remaining normal donor samples were processed by L.H. using the core protocol. PBMCs were isolated from blood collected 1-24 h earlier by using a Ficoll gradient and frozen at 5-20 9 10 6 cells/mL in FBS (Gemini, Broderick, CA) with 10% DMSO (Sigma, St Louis, MO) as previously described (23) . Sera were collected via centrifugation at 1000 9 g for 15 min, supernatant collection, and storage at À80°C. Table S1 . Additional testing on day 360 samples of subjects 1, 9, 13, and 14 was performed on stored sera at the Stanford Clinical Virology Laboratory by using the artus CMV MDx Rotor-Gene kit (Qiagen, Germantown, MD) targeting the CMV major immediate-early (MIE) gene. This test has a lower limit of 95% detection at~100 IU/mL of serum.
Viral load monitoring
Peptide libraries
Peptide libraries consisting of 15-amino acid peptides with an 11-amino acid overlap for the lengths of the polypeptides IE-1 and pp65 were purchased from GenScript (Piscataway, NJ).
Cell stimulation
Cells for normal donor controls and an entire time course of transplant recipient samples were thawed in a single batch as previously described (23) 
Stain for flow cytometry
Cells were first stained in an antibody to human C-C chemokine receptor (CCR)7 (BioLegend) diluted at 1:20 in PBS for 30 min at 37°C and then in Live/Dead aqua dye (Life Technologies, Carlsbad, CA) diluted at 1:400 in PBS for 20 min at room temperature. Cells were washed and spun down at 1250 rpm for 10 min, resuspended in surface stain prepared in Brilliant Stain Buffer (BD Biosciences), incubated for 30 min at RT, and then washed and spun down. Surface stain included an Fc receptor, CD16, for blocking. Cells were fixed by using the BD Cytofix/Cytoperm kit and protocol. Fixed cells were stained for 1 h at room temperature with intracellular antibodies diluted in 19 Perm/Wash buffer from the kit. Cells were washed and spun down and then resuspended in PBS with 1% paraformaldehyde (Alfa Aesar, Haverhill, MA). Before samples were run on a flow cytometer, they were resuspended in PBS. Compensation controls were prepared by using unstained and single stained cells or eBioscience Ultracomp eBeads (San Diego, CA).
Antibodies conjugated to fluorescein, phycoerythrin (PE) or four PE conjugates, allophycocyanin (APC) or APC conjugates, Alexa Fluor 700, or Brilliant Violet dyes 421, 570, 605, 650, 711, or 785 were specific for anti-human CD3 (HIT3a), CD4 (S3.5), CD8 (RPA-T8), CD14 (61D3), CD16 (3G8), CD19 (HIB19), CCR7 (G043H7), CD107a (H4A3), CD45RO (UCHL1), IFNc (B27), and tumor necrosis factor (TNF)a (mAb11) and were purchased from BioLegend, eBioscience, BD, Life Technologies, Abcam (Cambridge, UK), or Beckman-Coulter (Pasadena, CA).
Flow cytometry and data analysis
Samples were analyzed with the use of BD LSRII analyzers (Becton Dickinson, Franklin Lakes, NJ) configured for 18-color analysis at the University of Pennsylvania Flow Cytometry and Cell Sorting Resource Laboratory or the Stanford Shared FACS Facility. CS&T beads (BD Biosciences) were used to standardize analysis between instruments and from day to day.
Gating and data analysis
Flow cytometry data were analyzed by using FlowJo version 8.8.7 or 9.9.3 (Treestar, Ashland, OR). Most gates were manual, but Boolean gates were used to measure polyfunctionality. Positive gates for IFNc, TNFa, and CD107a were defined as shown in Figure 1 and used as input for FlowJo to make combinatorial Boolean gates for all possible combinations of expression of the three markers for a total of eight gates. Pie charts in Figure S2 were created by using the freely available software package SPICE (National Institute of Allergy and Infectious Diseases, Bethesda, MD) (24) . All other graphs were made with the use of GraphPad Prism 5 (La Jolla, CA).
Statistical analysis
Statistical analyses were completed by using GraphPad Prism 5 and Stata Statistical Software version 13.1 (StataCorp, College Station, TX). Equality of variances was measured by using Bartlett's test in Prism ( Figure S3 ). Due to varying sample number at different time points, generalized linear mixed models assuming a Gaussian distribution and log link were used to analyze trends of frequency of total cells changing over time and to identify differences between time points in STATA ( Figures 2-4 , S4). The threshold for significance of p-values was 0.05, with Bonferroni correction used to determine threshold of significance for multiple comparisons.
Results
Identification of polyfunctional CD8 + T cells We first developed an in vitro assay using 16-parameter flow cytometry to identify and characterize polyfunctional CD8 + CMV-specific T lymphocytes ( Figure S1 ). Responses to IE-1 or pp65 (25) were analyzed in CD8 + T cells at the indicated time points pretransplantation and posttransplantation ( Figure 1A ). Not all recipients had samples collected at every time point. For these studies, we define polyfunctionality as coexpression of two or three of IFNc, TNFa, and CD107a ( Figure 1B ). There was substantial patient-to-patient variation at day 0 in the frequency of polyfunctional IE-1-and pp65-responsive cells ( Figure 1C ) and cells expressing any combination of functions ( Figure S2 ). To determine whether this was due to biological or technical variation, we thawed multiple samples from one normal donor frozen on two occasions. Variation from the mean frequency of polyfunctional cells was lower within the samples from this individual than for the group of all transplant recipients ( Figure S3 ). This difference in variance was statistically significant (p < 0.05), suggesting that differences due to technical variation alone do not account for differences between patients and time points assessed.
Polyfunctional cells tend to be terminally differentiated effectors
To determine whether variation in polyfunctional CMVresponsive cells extended to the state of differentiation, we analyzed the memory/effector phenotype on the basis of CCR7 and CD45RO expression ( Figure 2A Figure 2B ). This phenotype was maintained posttransplantation. The proportion of polyfunctional CD8 + T cells that were effector or effector memory cells did not change over the time course ( Figure 2C , p > 0.05).
The population of CMV-responsive polyfunctional T cells increases in frequency of CD8 + T cells posttransplantation
The frequency of CD8 + T cells that are polyfunctional in response to IE-1 and pp65 increased during the course of 1 year posttransplantation (Figure 3 ). This increase is statistically significant over the time course (p < 0.001), and there was a statistically significant difference between day 0 and day 270 (p = 0.02) as well as day 360 (p < 0.001). There was no significant difference between any of the shorter time intervals evaluated. Monofunctional cells, in contrast, did not expand posttransplantation ( Figure S4 , all p > 0.05). The increase in CD8 + CMVresponsive cells appears to occur after day 90, correlating with removal of antiviral prophylaxis between 3 and 4 months in a majority of patients. We reasoned that changes in abundance, functionality, or specificity of CMV-responsive cells could be due to viral exposure. All PCR testing for CMV DNAemia for these patients was negative except for one PCR for patient 17 (Table S1 and Figure S5 ). To further investigate evidence of subclinical reactivation, we tested day 360 sera from four recipients for CMV DNAemia. These samples were chosen to represent patients with a range of CMV-responsive cellularity changes. All samples tested negative. Together, these data suggest that the expansion may not require detectable CMV exposure in the blood.
We next investigated other potential etiologies of T cell expansion. Because lymphodepletion is known to lead to rapid reexpansion of surviving lymphocyte pools (27) , we hypothesized that the expansion would be restricted to transplant recipients who had received lymphodepleting therapy. As expected, subgroup analysis of PBMCs from patients who received rabbit antithymocyte globulin (rATG) as induction therapy showed a significant increase in CMV-responsive CD8 + T cells over the time course (p < 0.001) and between day 0 and day 360 ( Figure 4A , p < 0.001). Interestingly, CMVresponsive cells also increased during the year after transplantation in those who received induction with antiinterleukin 2 receptor blockade or steroids alone that is not lymphodepleting ( Figure 4A , p < 0.001). In patients without lymphodepletion, the increase was statistically significant between day 0 with both day 90 (p = 0.006) and day 360 ( Figure 4A , p < 0.001). There was no statistically significant difference in the rates of CMV-responsive cell expansion among recipients who were lymphodepleted and recipients who were not lymphodepleted (p = 0.23). Therefore, lymphodepletion is not necessary for increased relative abundance of CMV-responsive, polyfunctional cells posttransplantation.
We next evaluated whether the increase in CMVresponsive cells was due to a shift between specificity to IE-1 versus pp65. IE-1-responsive T cells increase in frequency to a greater extent than do pp65-responsive T cells ( Figure 4B ). Both trajectories were statistically significant over the time course (p < 0.01), and there were statistically significant increases between day 0 and day 360 (p < 0.01). For IE-1-responsive cells, there was also a statistically significant increase from day 0 to day 180 (p = 0.02). The increase was initiated by day 90 in IE-1-responsive cells, whereas the kinetics were relatively delayed for pp65-responsive cells. There was a statistically significant difference in the increase of IE-1-and pp65-responsive cells (p < 0.0001), specifically at day 180 (p = 0.02) and day 360 (p = 0.006). These data suggest that there is a shift towards IE-1 specificity posttransplantation but that both specificities are affected.
T cell differentiation state-in particular, relative proportions of effector and na€ ıve T cells-can be affected by immunosuppression after transplantation. There was no difference in total CD8 + T cells between day 0 and day 360: 16.2 AE 2.36% versus 18.0 AE 2.80% of live PBMCs (p = 0.76). In contrast, the frequency of effector CD8 + T cells increased posttransplantation ( Figure 4C ). To address whether the increased frequency of polyfunctional CMVresponsive cells resulted from nonspecific expansion of the CD8 + effector population, we measured the frequencies of CD8 + T cells that were CMV-nonresponsive (
À effectors. For CD8 + effector cells that did not respond to IE-1 or pp65, there was no statistically significant increase ( Figure 4C , p = 0.05). For CMV-responsive effectors, there were increases from day 0 to days 180 (p < 0.001), 270 (p = 0.002), and 360 (p < 0.001). Comparison of the rate of increase of CMVnonresponsive and CMV-responsive effectors showed no association between the trends (p = 0.80). Therefore, the increase in effectors cannot fully account for the increase in CMV-responsive cells.
Discussion
In this study, we demonstrate that CMV-responsive CD8 + T cells expand posttransplantation. CMVresponsive CD8 + T cells are effectors or effector memory T cells pretransplantation and posttransplantation. The frequency of CMV-responsive CD8 + T cells increases posttransplantation in 16 patients who, based on standard of care monitoring, lack evidence of CMV viremia or disease. Therefore, overt infection may not be required for antigen-specific changes in immunity in the posttransplantation environment.
This study has several major strengths that make it a valuable approach to analyzing T cell immunity to CMV in the context of transplantation. First, the majority of studies of T cell responses to CMV have focused on ELISpot or four-to six-color flow cytometry. The use of 16-color analysis in this study provides substantial information that allows us to concurrently analyze functionality and memory phenotype. Second, studies on responses to IE-1 and pp65 have typically focused on production of IFNc, and our study extends this to polyfunctional T cells. Third, this study involves longitudinal analysis of changes posttransplantation and demonstrates that these findings apply to the recipients of two different organs.
Interpretation of these studies is complicated by several limitations. The small number of patients and heterogeneity of the population complicate our ability to draw conclusions. Viral load monitoring in this study was determined by the treating physician and standard of care; in the absence of weekly viral load monitoring, we cannot formally conclude a lack of viral replication. In addition, these studies used T cell function rather than MHC class I tetramer staining. As such, we cannot identify CMV-specific T cells independent of their function. Previous studies indicated that >90% of CMV-specific T cells are also CMV responsive (28, 29) . Therefore, we anticipate that our data are consistent with antigen-specific populations, but staining with tetramers for a variety of epitopes of IE-1 and/or pp65 would be required to fully analyze this.
This work contributes to the understanding of polyfunctionality in the context of CMV-responsive T cells in transplant recipients. Previous work on CMV in transplant recipients has generally focused on IFNc + T cells (30) (31) (32) (33) . Development of CMV disease several years posttransplantation is associated with defective CD8 + T cell production of IFNc and CD107a in response to CMV peptide (34) . The presence of polyfunctional CMV-responsive CD8 + T cells after lung transplant correlates with protection from viremia (35) . These studies focus on posttransplantation polyfunctionality; our study builds on these results by measuring changes in polyfunctionality from pretransplantation to posttransplantation. In addition, our results allow comparison of CMV in transplant recipients to studies of polyfunctionality in healthy CMV-seropositive individuals (11, 19) and in responses to other latent viral infections (19) (20) (21) . Consistent with our findings in immunosuppressed transplant recipients, the majority of CMV-responsive T cells are polyfunctional in healthy individuals (11, 19) . In responses to both HIV and CMV, there is an inverse correlation between viral load and the proportion of the T cell response that is polyfunctional (19) . This finding is consistent with antigen-specific expansion of CMVresponsive T cells in the absence of viremia. Because only one of the patients in our cohort developed clinical viremia, we cannot conclude that polyfunctionality confers protection. However, in combination with the previously identified correlation between polyfunctional T cells and viral load, our data suggest that expansion of CMV-responsive T cells may protect transplant recipients from viremia.
The lack of detected viral reactivation suggests that controlled and/or subclinical reactivation may also be relevant to the T cell response. Transient CMV viremia controlled by prophylaxis or immunity has been documented (36) . Heart, lung, and kidney transplant recipients with CMV viremia had an expansion of T cells producing IFNc in response to CMV (37) . In another study, asymptomatic CMV seropositive renal transplant recipients (6-732 days posttransplantation) had a higher frequency of IFNc + pp65-responsive CD8 + T cells than did seropositive healthy volunteers (38) . Thus, IFNc + CMV-responsive CD8 + T cells can expand posttransplantation in patients with or without detectable viremia. Our findings extend this observation to polyfunctional CD8 + T cells and begin to define the kinetics of this increase.
In contrast to the increase in CMV-responsive CD8 + T cells, only one of our cohort of transplant recipients had CMV viremia detected in standard of care testing or in our subsequent analysis of day 360 samples. There may have been viremia below the threshold of detection, asymptomatic viremia, or virus localized to tissues. Such viral replication could promote T cell expansion without being detectable in peripheral blood. Subclinical viremia may be more likely to occur in patients with seropositive allografts; however, numbers in this study were insufficient to draw conclusions about this possibility. In support of the hypothesis that exposure to virus is the cause, the expansion is first observed at day 180, which is after termination of antiviral prophylaxis in all subjects included in the statistical analyses. The recipient who experienced viremia (patient 17) had an expansion of polyfunctional cells that was either concurrent with or after the patient's viremic episode. These data are consistent with virus-induced expansion, but we were not able to obtain appropriately timed samples in this patient to confirm this interpretation. Interestingly, in one recipient (patient 9) with a documented episode of viremia while receiving immunomodulatory treatment for nontransplant-related disease before enrollment, approximately 30% of pretransplantation CD8 + T cells were responsive to CMV, suggesting that a persistent expansion of CMV-responsive T cells resulted from prolonged exposure to high levels of viral replication.
Another factor suggesting controlled reactivation as the cause of T cell expansion is the differential kinetics of response to IE-1 and pp65 ( Figure 4B ). IE-1 is a transcription factor expressed early in the CMV life cycle that is required for the expression of other CMV genes (39, 40) , including pp65 (41) . In contrast, pp65 is an important structural component of CMV virions (42) and is expressed much later in the viral life cycle. T cell responses to IE-1 form in response to rapidly controlled reactivation that is otherwise undetectable and can preclude the expression of pp65 by reactivated virus (43) . Responses to IE-1, and not to pp65, have been shown to correlate with protection from CMV disease in heart and lung transplant recipients (30) . Differential kinetics are consistent with this finding, although our results do not address protection.
Analysis of viral load in healthy individuals demonstrated that CMV DNA is virtually undetectable in the majority of the healthy CMV-seropositive population, with the exception of those over the age of 70 (44) . Impaired control of CMV in the aged promotes elevated viral load. The over-70 cohort have expanded CMV-responsive T cell populations and elevated CMV-specific antibodies (44) . These immune phenotypes are detectable at earlier ages, before viremia is detectable. Consistent findings in mice support this hypothesis: in mice infected with murine CMV defective in replication and spread, production of immunogenic proteins by cells infected during primary infection was sufficient to drive long-term expansion of memory T cells (10) . These studies indicate that detectable viremia is not necessary for the expansion of T cells in response to CMV.
An alternative potential trigger of the increase in CMVresponsive T cells in our study population is exposure to donor alloantigen. Published research demonstrates that CMV specific T cells can cross-react with alloantigen (45, 46) . In addition, memory T cells are resistant to lymphodepletion (47, 48) , which can lead to increased levels of alloreactive memory T cells (27) . Therefore, a population of CMV-responsive T cells could contain alloreactive cells that expand in response to donor alloantigen. Rejection can be prevented by the immunosuppressive treatment in these recipients.
Another potential cause is nonspecific homeostatic expansion. The frequency of CD8 + T cells in the blood is unchanged posttransplantation. Therefore, homeostatic expansion does not enlarge the CD8 + T cell niche, and any changes are within the preexisting niche. Specifically, immunosuppression and lymphodepletion can cause expansion of memory and effector T cells at the expense of other T cell populations (47, 48) . We assessed the potential effects of lymphodepletion through comparison of CMV-responsive CD8 + T cells in transplant recipients with and without lymphodepleting induction therapy. The CMV-responsive T cell expansion occurred in both groups of patients. A previous study of T cell responses to CMV found no difference in IFNc production by ELISpot over the course of 1 year posttransplantation between renal transplant recipients with and without lymphodepleting induction (49) . Our data are consistent with this study and extend the finding from IFNc to polyfunctional CMV-responsive T cells. In addition, CMV-responsive effector cells expand to a greater degree than do CMV-nonresponsive effector cells ( Figure 4C ). If homeostatic proliferation were the cause, there would be no difference in the expansion of these populations. In our view, antigen-specific proliferation is a more likely etiology than homeostatic proliferation, suggesting that these T cells are involved in ongoing immune responses.
Our results indicate that CMV-seropositive recipients with asymptomatic or no viremia have functional CMV-responsive T cells both pretransplantation and at 1 year posttransplantation. Depending on the antigenic stimulus for the expansion, these cells may be protective (CMV responsive) or pathogenic (alloantigen responsive). Therefore, larger studies should explore whether this T cell phenotype correlates with protection from CMV. If so, then transplant recipients could be evaluated for T cell responses and, in some cases, have immunosuppressive and antiviral doses reduced to allow T cells to control CMV posttransplantation. Such therapeutic changes could contribute to improving CMV control and long-term allograft survival (50) .
Supporting Information
Additional Supporting Information may be found in the online version of this article. Table S1 : CMV DNAemia PCR results. PCRs completed as indicated in Materials and Methods. Of the 18 patients in this cohort (including patients 9 and 17 excluded as discussed in Materials and Methods), 11 were monitored for CMV DNAemia between 1 and 14 times during the study as part of routine care. The other seven patients had no CMV viral load testing as part of their posttransplantation course and have "N/A" indicated under both viral load and result. If the result is listed as "negative," there was no CMV above the threshold of detection. *References the one positive viral load result. CMV, cytomegalovirus; PCR, polymerase chain reaction. 
